Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Agree but think inhalers will pick up the slack as they also kill off the IV revenue line, if they are as effective as I think they may be.
Now if they aren't as effective, then the IV revenue line will keep producing.
Rem full approval. If we would have had a broader application, instead of for the critically ill only on vents, it's possible the Rem full approval would have nixed our EUA app.
I wondered why at the time it was so narrowly defined, thinking maybe it was easier to get approval, but now I know it's because he wanted to sidestep this Rem approval.
Proof that Javitt is 4 steps ahead again. Everyone had the idea that having Harris on the team gave us a way to get info "to" Trump, when that was backwards. Javitt's connections at the FDA and in this adminstration enabled info to get "from" Trump and the FDA back to Javitt. He saw this coming 4 weeks ago. Proof was his application specifically worded to sidestep this landmine that no one but him saw coming. He has our backs again and has this game figured out. He protected Relief/NeuroRx by his prior-planning.
PUMA is gone off the LVL2, so they are topped off or have their shorts covered. Now seeing .01 cent jumps up and down. No volume lately means no price movement, but several weeks ago, we had volume and still no movement. I believe it was due to Puma and others playing their games holding this down.
Anyone else notice PUMA is gone from Level 2?
TDS is a real disease. Those that have it need professional help.
Wow. That's what I call big pharma in the making.
Thank you!
Thank you so much!
Recently (in the last week maybe) someone posted a brief summary of everything that RLF has done and things still pending, all in one post. Now that I want to share Rlf with someone, I thought pointing them to that post would be the best way, but I can't find it. Does someone remember where it is?
Yes! The Mon's jumped out at me too! Prepared for nothing, but hoping for something.
Ps. Trying to not think about, maybe they produce a PR when something actually happens and not on a certain day. Lol
Fun facts here. Last few PR's by day of the week:
8/6 Thurs
8/20 Thurs
8/31 Mon
9/4 Fri
9/15 Tues
9/21 Mon
9/23 Wed
9/28 Mon
9/30 Wed
10/8 Thurs
Draw your own conclusions.
https://relieftherapeutics.com/news/
Actually a little more than Nasdaq uplisting. He guided CPRX through an IPO.
Relief Therapeutics Appoints Industry Veteran, Jack Weinstein, as Chief Financial Officer and Treasurer
https://relieftherapeutics.com/relief-therapeutics-appoints-industry-veteran-jack-weinstein-as-chief-financial-officer-and-treasurer/
Approving RLF-100 would give the FDA a way to flip off Trump and the media would be all over it. Just sayin...
In search of a new screen for my only 2 month old phone. Worn out in one small spot. Apparently pulling the screen down 10,000 times inside of one week, trying to refresh, is the maximum limit.
Staying long. EUA any time now.
I considered that as well, for maximum impact, but how long do you think they can keep a lid on it, before news gets out? FDA updates their site and word spreads fast.
With the EUA imminent, I thought it would be interesting to look back at the last few EUA's the FDA gave, and see what time of day they hit the news wires. As I was researching, I noticed Gilead PR'd they were making 1M courses of Rem on 4/30. (Sound familiar?) On 5/1 at 3:50p ET, news showed up about their EUA. At 3:56p ET, Trump announced it. At 4:09p ET, news started popping up everywhere. On their EUA on 8/28, it popped up in news on TD Ameritrade at 4:45p ET. So I'm thinking the FDA typically issues the EUA in the late afternoon, after the market closes? Right? Or they send an email that afternoon, and then the company PR's it after market closes? Either way, that's what has happened for the Gilead ones. We do have a dual market issue to consider and we know NeuroRX/Relief likes to PR at 1a or 130a ET, but I don't think they can sit on this one until their usual time, if it does come in, in the afternoon EST. Draw your own conclusions, but I'm thinking when it comes, it will be PR'd after market closes in NY.
I love the fact that I'm now thinking about "when" this will hit, as opposed to "IF" it will hit. I do believe it's imminent, but may happen after the FDA receives the additional data this week.
I think the 50/50 is already figured in, because the population #'s are about 1/2 of actual.
Think it was just a ride around the block, then back in.
https://www.foxnews.com/
Headline just said Trump visits supporters.
No one has ever accused Trump of not having a good set of lungs. Just sayin...
I'm not necessarily disagreeing, just didn't understand why you referenced a post about trial data and then threw in an opinion on Trump's lungs. I wasn't making the jump.
I think it's fair to say most 74 yr olds that get covid will have some damage.
How do you get from xray results in the trial at Houston Methodist (post you referred to) to Trumps lungs being damaged?
Why would anyone want a buyout, until this well is tapped out. That would cap our profit. This could run big 3 or 4 different times.
Maybe we'll have an answer soon and you can update the spreadsheet.
In all fairness, @J-Belfort pointed out to me that there are multiple postings for the same position. If I drill down to the details, it seems like most of the positions posted are referring to an opening in Philly.
And you believe those figures? At ground zero, China probably has 10x what we have had.
I think it would help get the word out about Aviptadil/RLF-100, if we would all start referring to it as Samivir and Samiair in our posts, along with Aviptadil/RLF-100, as much as possible. As we saw last night, there are so many drugs similar in name, even these so-called experts, in the news, can't get it right. Aviptadil, Avifavir, Favipiravir, etc.
In a couple of days, Samivir/Samiair might just be household words.
You're welcome, on the other post.
In regards to this one, was just thinking about that too. If he takes it and he's one of the few that doesn't get better, we're done.
They are the same drug.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=158659278
Avifavir has trials in Boston and Miami.
Think he said Avifavir, which does have trials all over Europe as he said, and in the US (Boston & Miami.) Also known as Favipiravir and Avigan.
It's at 2:00 minute mark.
https://video.foxnews.com/v/6196713381001#sp=show-clips
https://www.trialsitenews.com/russia-ministry-of-health-approves-avifavir-favipiravir-for-covid-19-patients-cuts-duration-of-illness-by-over-50/
https://www.clinicaltrials.gov/ct2/results?cond=COVID-19&term=&type=&rslt=&age_v=&gndr=&intr=Favipiravir&titles=&outc=&spons=&lead=&id=&cntry=&state=&city=&dist=&locn=&rsub=&strd_s=&strd_e=&prcd_s=&prcd_e=&sfpd_s=&sfpd_e=&rfpd_s=&rfpd_e=&lupd_s=&lupd_e=&sort=
07:43:57
RLF.SW Estim: 0.546
Buy/Ask - 243'290 / 5'000
Where does this take us tomo? Shorts having a coronary right now?
Very well written article today.
https://microcapdaily.com/everybody-is-talking-about-rlf-100-aviptadil-relief-therapeutics-holding-ag-otcmkts-rlftf/128057/
Relief Therapeutics Holding AG (OTCMKTS: RLFTF) is on a powerful rise up the charts and emerging as the darling of small caps as its coronavirus therapeutic RLF-100 (Aviptadil) gains serious traction. RLF-100 (Aviptadil) is believed to be the first COVID therapeutic to block replication of the SARS-CoV-2 virus in human lung cells and monocytes while at the same time preventing synthesis of cytokines in the lung. It is a patented formulation of Aviptadil (synthetic human Vasoactive Intestinal Polypeptide, VIP), which has been granted FDA fast track designation, FDA emergency use IND authorization, and an expanded access protocol.
Relief just completed a capital raise of CHF 17,949,600 which puts the Company’s cash position at approximately CHF 48,000,000 ($52.2 million USD) which will be used primarily to fund the ongoing Fast Track FDA trial of RLF-100 (IV) in COVID-19 acute respiratory distress syndrome (NCT04311697) and the RLF-100 (inhaled) trial for the treatment of non-acute lung injury in COVID-19 (NCT04360096) as well as to run a phase 3 study in Europe. Relief and its partner, NeuroRx anticipate reporting top-line data from the ongoing randomized, double-blinded, placebo-controlled trial of intravenously-administered RLF-100 before the end of 2020. The trial of inhalation-administered RLF-100 is slated to begin enrollment within the coming weeks. RLF-100 is starting to get noticed by mainstream press including articles in Reuters, NyTimes and Fox News. According to the Reuters article “Relief Therapeutics sees 60-70% chance of COVID-19 drug approval” Relief Therapeutics’ chairman said he was optimistic its RLF-100 (Aviptadil) drug will win approval for treating COVID-19 patients in a matter of months.”
Relief Therapeutics and NeuroRx Announce Final Manufacturing Validation of RLF-100 for Phase 2b/3 Clinical Trial in Patients with COVID-19 Associated Acute Respiratory Distress Syndrome | Relief TherapeuticsRelief Therapeutics Holding AG (OTCMKTS: RLFTF) is a Swiss-based publicly-traded drug development company with a vision of becoming a dominant player in the lucrative biotech and pharmaceutical space. Relief strongly believes that only by effectively treating patients will its investors realize significant return on investment. The Company’s areas of interest cover a broad range of indications from niche (orphan indications) up to larger markets. Relief experimental drugs are primarily of natural origin and have been already tested or used safely in the clinical setting thereby minimizing risks and maximizing efficacious potential. Relief focuses on late stage clinical assets and strives to reduce development times and costs to quickly reach high quality decision-enabling results.
RLF-100™ is in FDA-approved phase 2b/3 clinical trials for the treatment of critical COVID-19 in the US. A readout by the study’s Data Monitoring Committee is expected within the next month. European trials with RLF-100TM are in preparation and are scheduled to start in Q1 2021. Relief and its partner, NeuroRx anticipate reporting top-line data from the ongoing randomized, double-blinded, placebo-controlled trial of intravenously-administered RLF-100 before the end of 2020. The trial of inhalation-administered RLF-100 is slated to begin enrollment within the coming weeks. RLF-100 is the first COVID-19 therapeutic to demonstrate the ability to block replication of the SARS-CoV-2 virus in human lung cells and monocytes, while preventing synthesis of cytokines in the lung. Since July 2020, severe COVID-19 patients have been treated with RLF-100 under U.S. FDA Emergency Use Investigational New Drug (IND) authorization and Expanded Access Protocol authorization for the treatment of respiratory failure in COVID-19. According to a recent Reuters article: “Relief Therapeutics sees 60-70% chance of COVID-19 drug approval” Relief Therapeutics’ chairman said he was optimistic its RLF-100 (Aviptadil) drug will win approval for treating COVID-19 patients in a matter of months.”
Relief has been busy in recent weeks; they finalized their partnership agreement with NeuroRx for the commercialization of RLF-100™(Aviptadil) worldwide. The two organizations have agreed to share all profits from sales of RLF-100 for all indications related to COVID-19 and potentially other respiratory indications on a global basis. They have agreed that NeuroRx will lead commercialization in the United States, Canada, and Israel, while Relief will lead commercialization in Europe and the rest of the world. Profits from sales will be allocated to Relief and NeuroRx on a 50/50 basis in the U.S., Canada and Israel, 85/15 (in favor of Relief) in Europe, and 80/20 (in favor of Relief) in all other territories. As part of their agreement, Relief and NeuroRx intend to pursue the issuance of trademarks on RLF-100. NeuroRx shall prosecute such trademarks in the U.S., Canada and Israel, while Relief shall prosecute trademarks in all other territories.
To Find out the inside Scoop on Relief Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
RLFTF
Last week NeuroRx submitted a request for an Emergency Use Authorization (EUA) with the US FDA for the use of RLF-100™ Aviptadil in patients who are receiving intensive care and who have exhausted all approved treatments. The submission is based on a case-control study that compared patients who were treated with RLF-100™ (n=21) to those receiving maximal standard of care treatment (n=30) in the same ICU by the same medical staff. Patients treated with RLF-100™ demonstrated a 3-fold advantage in survival, recovery from respiratory failure, and other parameters indicative of meaningful clinical improvement. Hypotension was seen in two Aviptadil patients and was successfully managed with pressors. Diarrhea was seen in 4/21 Aviptadil-treated patients and 3/30 control patients. The results have been submitted to a peer-reviewed journal.
Relief also has completed a capital increase pursuant to a drawdown of its Share Subscription Facility (SSF) with the Company’s main shareholder GEM Global Yield Fund LLC SCS (“GEM”). Funds raised amount to CHF 17,949,600. The available cash on the balance sheet of the Company, after receipt of the funds, will be approximately CHF 48,000,000 ($52.2 million USD) and will be used primarily to fund the ongoing Fast Track FDA trial of RLF-100 (IV) in COVID-19 acute respiratory distress syndrome (NCT04311697) and the RLF-100 (inhaled) trial for the treatment of non-acute lung injury in COVID-19 (NCT04360096) as well as to run a phase 3 study in Europe. Relief believes that with the conclusion of this raise, its capital resources will be sufficient to support its planned operations through 2022, without taking into account potential revenues generated from sales of RLF-100. Execution of the SSF, together with the latest exercises of stock options, brings the total amount of shares outstanding to 2,580,068,581.
Relief and its partner NeuroRx have established supply chain agreements and ordered sufficient drug substance (RLF-100TM) to prepare to treat 1 million patients with COVID-19. The partners contracted with Nephron Pharmaceuticals, Inc., Bachem Americas, as well as a leading nationwide pharmaceutical logistics partner in order to ensure overnight commercial supply to US hospitals, should RLF-100™ continue to succeed in clinical trials.
Dr. Raghuram (Ram) Selvaraju, Chairman of the Board of Relief commented: “In normal circumstances, it would be prudent to wait until all the data are in before initiating commercial scale-up. However, in an environment where more than 40,000 Americans are contracting COVID-19 daily and 800 are dying each day, there is not a moment to lose in ensuring that sufficient quantities of RLF-100™ will be available, should the clinical trials succeed in proving safety and efficacy. We are living in unprecedented times, which call for flexibility and innovative thinking, in and outside the clinic. Therefore, we have taken the necessary steps to match the rapid clinical development of RLF-100TM by establishing a supply chain capable of scaling up to meet the urgent medical needs of critical COVID-19 patients.”
We have a Monster Pick Coming. Subscribe Right Now!
Relief is on a powerful rise up the charts in recent months emerging as the darling of small caps as its coronavirus therapeutic RLF-100 (Aviptadil) gains serious traction. Relief just completed a capital raise of CHF 17,949,600 which puts the Company’s cash position at approximately CHF 48,000,000 ($52.2 million USD) which will be used primarily to fund the ongoing Fast Track FDA trial of RLF-100 (IV) in COVID-19 acute respiratory distress syndrome (NCT04311697) and the RLF-100 (inhaled) trial for the treatment of non-acute lung injury in COVID-19 (NCT04360096) as well as to run a phase 3 study in Europe. Relief and its partner, NeuroRx anticipate reporting top-line data from the ongoing randomized, double-blinded, placebo-controlled trial of intravenously-administered RLF-100 before the end of 2020. The trial of inhalation-administered RLF-100 is slated to begin enrollment within the coming weeks. RLF-100 is starting to get noticed by mainstream press including articles in Reuters, NyTimes and Fox News. According to the Reuters article “Relief Therapeutics sees 60-70% chance of COVID-19 drug approval” Relief Therapeutics’ chairman said he was optimistic its RLF-100 (Aviptadil) drug will win approval for treating COVID-19 patients in a matter of months.” Relief stock took off in the last week of July after the FDA granted expanded access protocol for treatment of Respiratory Failure in COVID-19 with RLF-100. Aviptadil is the first coronavirus therapeutic to demonstrate the ability to block replication of the virus in human lung cells and monocytes, while at the same time preventing synthesis of cytokines in the lungs. Microcapdaily covers Relief on the regular and first reported on the Company on August 3 as Relief was running northbound off its $0.05 base. We will be updating on Relief on a daily basis so make sure you are subscribed to microcapdaily.com so you know what is going on with Relief.
Thank you for the explanation.
Also, thank you @J-Belfort for the PM's further explaining it for me. (Can't reply without upgrading my account.)